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http://dx.doi.org/10.1016/j.ccr.2014.01.025SUMMARYCellular transformation by oncogenic RAS engages theMAPK pathway under strict regulation by the scaffold
protein KSR-1. Here, we report that the guanine nucleotide exchange factor GEF-H1 plays a critical role in a
positive feedback loop for the RAS/MAPK pathway independent of its RhoGEF activity. GEF-H1 acts as an
adaptor protein linking the PP2A B’ subunits to KSR-1, thereby mediating the dephosphorylation of KSR-1
S392 and activation of MAPK signaling. GEF-H1 is important for the growth and survival of HRASV12-trans-
formed cells and pancreatic tumor xenografts. GEF-H1 expression is induced by oncogenic RAS and is corre-
lated with pancreatic neoplastic progression. Our results, therefore, identify GEF-H1 as an amplifier of MAPK
signaling and provide mechanistic insight into the progression of RAS mutant tumors.INTRODUCTION
The centrality of the RAS/MAPK pathway in promoting tumor
formation is underscored by the high frequency of gain-of-
function mutations in RAS family members and other com-
ponents of the pathway in human cancers. KRAS has a partic-
ularly high mutation frequency of 30%–50% in colon and
greater than 90% in pancreatic adenocarcinomas (Oliveira
et al., 2007; Mulcahy et al., 1998). The importance of RAS is
a reflection of its essential role in mediating the transduction
of signals from growth factor receptors to pathways that regu-Significance
Mutational activation of RAS occurs in over 90%of pancreatic c
of tumorigenesis. However, the mechanism of RAS-mediated
that GEF-H1 is necessary for optimal RAS/MAPK pathway si
mutant cells. GEF-H1 expression is induced by oncogenic R
providing an amplifying loop for RAS/MAPK signaling. Our resu
pendencies of oncogenic RAS, which may ultimately improve
Clate transcription, cell cycle progression, cell shape, and cell
survival, all of which are commonly disturbed in cancer (Mac-
ara et al., 1996). RAS engages diverse signaling pathways,
including RAF, PI3K, RAL-GDS, and TIAM-1, each of which
are also subject to activating mutations in cancer (Davies
et al., 2002; Samuels and Velculescu, 2004; Philp et al.,
2001; Sjo¨blom et al., 2006; Greenman et al., 2007; Engers
et al., 2000). RAS activation is coupled to transcription through
the activation of the MAPK cascade, involving the sequential
phosphorylation and activation of the serine/threonine kinases
RAF (MAPKKK), MEK1/2 (MAPKK), and ERK1/2 (MAPK)ancers and is required for both the initiation and progression
cellular transformation is not fully understood. Here, we find
gnaling and contributes to the growth and survival of RAS
AS and is elevated in pancreatic tumor samples, thereby
lts, therefore, extend our understanding of the signaling de-
the development of RAS-pathway-directed therapeutics.
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GEF-H1 Is Required for Oncogenic RAS Signaling(Moodie et al., 1993; Warne et al., 1993; Zhang et al., 1993;
Vojtek et al., 1993).
The Kinase Suppressor of RAS (KSR-1) was originally
identified in genetic screens in Drosophila and Caenorhabditis
elegans designed to isolate mutations in genes that modify the
phenotypes associated with oncogenic RAS alleles (Jacobs
et al., 1999; Therrien et al., 1995; Sundaram and Han, 1995). In
mammalian cells, KSR-1 acts as a molecular scaffold to
assemble a macromolecular complex of MAPK pathway com-
ponents to facilitate efficient signal transmission (Therrien
et al., 1996; Michaud et al., 1997; Cacace et al., 1999; Morrison,
2001) and is required for mutant RAS-mediated cellular transfor-
mation (Nguyen et al., 2002; Lozano et al., 2003). KSR-1 also
functions as a gate to control flux through the MAPK pathway.
In quiescent cells, KSR-1 is phosphorylated on S297 and S392
by C-TAK1 and held in an inactive state in the cytosol by 14-3-
3 proteins (Ory et al., 2003). RAS activation stimulates the
dephosphorylation of KSR-1 on S392, resulting in its transloca-
tion to the plasma membrane where it potentiates MAPK
signaling (Ory et al., 2003).
Genetic studies performed in model organisms showed
that mutations in the PP2A phosphatase phenocopied a
loss of KSR-1 function in a RAS mutant background (Wassar-
man et al., 1996; Sieburth et al., 1999), suggesting that
PP2A is a positive regulator of KSR-1. PP2A was subsequently
shown to be the critical phosphatase required for dephos-
phorylation of KSR-1 on S392 in response to activated
RAS (Ory et al., 2003). PP2A is a heterotrimeric serine/
threonine protein phosphatase composed of a catalytic (C),
structural (A), and regulatory (B) subunit. The catalytic and
structural subunits are constitutively associated to form a
core complex to which one of many B subunits can bind (Jans-
sens and Goris, 2001). Four different B subunits (B, B’, B’’, and
B’’’) exist in mammals that determine the localization and sub-
strate specificity of the holoenzyme (Janssens and Goris,
2001). The A and C subunits constitutively associate with
KSR-1, whereas association of the B’ subunit is induced only
upon RAS activation (Ory et al., 2003). The mechanism by
which the B’ subunit is recruited to KSR-1 has yet to be
elucidated.
GEF-H1, which is encoded by ARHGEF2, is a microtubule-
associated guanine nucleotide exchange factor (GEF) for the
Rho family of small GTPases (Ren et al., 1998). Several lines
of evidence have highlighted the transforming potential of
GEF-H1. ARHGEF2 is amplified in hepatocellular carcinoma
(Cheng et al., 2012) and is a transcriptional target of gain-of-
function p53 mutants (Mizuarai et al., 2006) and the metas-
tasis-associated hPTTG1 (Liao et al., 2012). Truncated versions
of GEF-H1 can transform NIH 3T3 cells (Whitehead et al., 1995)
and induce tumor formation in nude mice (Brecht et al., 2005).
ARHGEF2 is one of six genes significantly downregulated in
response to imatinib treatment in gastrointestinal tumors
(Frolov et al., 2003). In addition, ARHGEF2 was identified in a
genome-wide pooled small hairpin RNA (shRNA) screen de-
signed to identify genes that are required for the survival of
human breast, colon, lung, ovarian, and pancreatic cell lines
(Marcotte et al., 2012). These data suggest that GEF-H1 may
be a marker for and/or contribute to tumorigenesis in multiple
contexts.182 Cancer Cell 25, 181–195, February 10, 2014 ª2014 Elsevier Inc.RESULTS
GEF-H1 Contributes to the Survival of a Subset of
Human Cancer Cell Lines, and Its expression Is
Regulated by the RAS/MAPK Pathway
GEF-H1 was found to contribute to the competitive growth
characteristics of 18 out of 73 cell lines, 13 of which were identi-
fied in the original shRNA screen and 5 of whichwere identified in
our secondary screen (Figure 1A and Table S1 available online).
For further validation, we selected three of these cell lines and
stably infected them with two distinct lentiviral hairpins directed
against GEF-H1. Cells depleted of GEF-H1 exhibited decreased
growth and increased death relative to control hairpin-express-
ing cells as assessed by caspase 3 cleavage (Figures 1B and
S1A–S1H). These data suggest that GEF-H1 is important for
cell growth and survival in several human cell lines derived
from different tumor types.
We noted that GEF-H1 dependency was enriched in RAS/
BRAF mutant cell lines (13 of 30 [43.3%]) compared to RAS/
BRAF wild-type cell lines (5 of 43 [11.6%]). GEF-H1 was found
to contribute to cell growth/survival in 10 of 25 (40%) KRAS
mutant pancreatic cancer cell lines with little effect on the three
wild-type KRAS pancreatic cancer cell lines (Table S1). We
therefore explored the possibility that GEF-H1 sensitivity in
some cellular contexts is epistatic with gain-of-function muta-
tions in the RAS/MAPK pathway. Because elevated expression
of GEF-H1 is transforming in NIH 3T3 cells (Whitehead et al.,
1995), we examined the ability of mutant RAS family members
to induce GEF-H1 expression in a common isogenic cellular
background. We observed that GEF-H1 protein levels were
increased in cells transformed by each mutant RAS family mem-
ber compared to nontransformed cells (Figure 1C). We next
determined whether the induction of GEF-H1 expression was a
direct result of activated RAS or a secondary consequence of
the transformed state. We used a murine embryonic fibroblast
(MEF) cell line expressing a hydroxytamoxifen (4-OHT)-inducible
form of HRASV12 (ER:HRASV12) (Gupta et al., 2007) and found
that GEF-H1 expression increased within 15 min of ER:HRASV12
induction and continued to increase with progressive elevation
of ER:HRASV12 expression (Figure 1D, upper panel). Cells
treated with vehicle control (EtOH) exhibited no change in
GEF-H1 levels (Figure 1D, lower panel). These data show that
GEF-H1 is induced acutely in response to expression of
HRASV12. MAP kinase pathway activation followed a bimodal
distribution, peaking at 15 min and 8 hr after HRASV12 induction,
but decreasing over intermediate time points, as has been previ-
ously shown (Gupta et al., 2007).
ARHGEF2 Is a Transcriptional Target of the RAS/MAPK
Pathway
To assess whether GEF-H1 expression was dependent on
MAPK activation, we treated OV-90, HCT116, and Panc 02.03
cells with the MEK1/2 inhibitors PD98059 and UO126 and found
that the GEF-H1 protein level decreased following MEK1/2
inhibition (Figure 2A). Similar findings were observed in
HRASV12-transformed NIH 3T3 cells (Figure 2B). We noted that
the GEF-H1 mRNA level was elevated 2-fold in HRASV12-trans-
formed NIH 3T3 cells relative to wild-type cells (Figure 2C)
and sought to determine whether ARHGEF2 was a direct
Figure 1. GEF-H1 Contributes to the Sur-
vival Fitness of a Subset of Human Cancer
Cell Lines, and Its Protein Expression Is
Regulated by the RAS/MAPK Pathway
(A) Schematic graphical representation of 13
GEF-H1-sensitive cell lines arranged according to
the p values for the normalized Genetic Activity
Rank Profile (zGARP) score across 75 cell lines
(Marcotte et al., 2012). The fraction of GEF-H1-
sensitive cell lines from each tumor type is de-
picted by the pie chart. The number of cell lines
showing GEF-H1 dependency is indicated within
the area of each slice.
(B) Bright field images of the indicated cells
6 days following infection and selection with
hairpin control (shGFP) or human GEF-H1 shRNA
(shGEFh2) lentivirus. Scale bars, 100 mm.
(C) Immunoblot analysis of GEF-H1 and RAS
expression in NIH 3T3 cells stably expressing
vector, T7-HRASV12, T7-KRASD12, or T7-
NRASD12. pERK indicates level of MAPK pathway
activation and total ERK and tubulin served as
protein loading controls.
(D) Immunoblot analysis of GEF-H1 expression
following acute induction of ER:HRASV12 with
100 nM 4-OHT (upper panel) or treatment with
vehicle control (lower panel) over the indicated
period of time.
See also Figure S1 and Table S1.
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footprinting and CpG island enrichment, we identified a 1.9 kb
region upstream of the first exon of murine Arhgef2 predicted
to contain the putative promoter, and we cloned this region
into a luciferase reporter (Figure 2D). Expression of HRASV12
induced a 7-fold increase in the normalized Arhgef2 promoter-
mediated luciferase activity compared to NIH 3T3 cells express-
ing the Arhgef2 promoter alone and was quenched following
MEK inhibition (Figure 2E). Together, these data show that
Arhgef2 is a transcriptional target of the RAS/MAPK pathway
and that the elevated GEF-H1 protein level observed in
HRASV12-transformed cells are, at least in part, due to elevated
transcription.Cancer Cell 25, 181–195,GEF-H1Contributes toCell Survival
and Growth in HRASV12-
Transformed Cells
We next sought to determine whether
GEF-H1 was important for HRASV12-
mediated cellular transformation. We
stably knocked down murine GEF-H1 in
HRASV12-transformed NIH 3T3 cells
using two distinct GEF-H1 lentiviral hair-
pins (Figure 3A), which resulted in
increased apoptosis as measured by
caspase 3 cleavage (Figure 3B). We also
observed that stable depletion of GEF-
H1 suppressed anchorage-independent
growth by 90% compared with parental
HRASV12-transformed cells or trans-
formed cells expressing a nontargeting
hairpin (Figures 3C and S2A).To address the role of GEF-H1 in supporting tumor formation
of HRASV12-transformed NIH 3T3 cells, we generated sub-
cutaneous tumor xenografts in NCr nude mice. Parental and
shGFP-expressing cells formed tumors within 10 days of injec-
tion, while GEF-H1-depleted cells demonstrated attenuated
tumor growth (Figures 3D, 3E and S2B). Moreover, GEF-H1-
depleted tumors exhibited increased caspase 3 cleavage
relative to parental and hairpin controls (Figure 3F). To further
examine the role of GEF-H1 in HRASV12-mediated cell survival,
we monitored the behavior of MEFs derived from Arhgef2
knockout mice (Arhgef2/) following ectopic expression of
HRASV12 (Figure 3G). Extensive cell death was observed in
Arhgef2/ compared to wild-type MEFs following HRASV12February 10, 2014 ª2014 Elsevier Inc. 183
Figure 2. Arhgef2 Is a Transcriptional
Target of the RAS/MAPK Pathway
(A) Immunoblot analysis of GEF-H1 expression in
cancer cell lines after treatment with DMSO,
PD98059 (30 mM), or UO126 (10 mM) for 48 hr.
(B) HRASV12-transformed NIH 3T3 cells were
treated with DMSO, PD98059, UO126, or
LY294002 for 48 hr, and GEF-H1 expression was
assessed by western blot. pERK and ERK indicate
phosphorylated and total ERK, respectively,
whereas pAKT and AKT indicate phosphorylated
and total AKT, respectively.
(C) The GEF-H1 mRNA level in NIH 3T3 cells
expressing vector or T7-HRASV12 was quantified
by real-time PCR and normalized to tubulin. Levels
are represented as fold change over vector-
expressing cells.
(D) Schematic representation of the putative pro-
moter region of murine Arhgef2 showing the highly
conserved transcriptional start site (TSS) from the
UCSC genome browser.
(E) pArhgef2Luc was co-transfected with empty
vector or T7-HRASV12 expression plasmid and
treated with PD98059. Luciferase activity was
normalized to renilla expression and is repre-
sented as fold change over empty vector-ex-
pressing cells (left graph). Lysates were assayed
for RAS expression and MAPK activation by
western blot (right panel). All data are represen-
tative of three independent experiments ± SEM.
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expressing HRASV12 restored cell viability. These data show
that GEF-H1 contributes to HRASV12-mediated cell transforma-
tion and cell viability in vitro and in vivo.
GEF-H1 Induction and Dependency in BRAFV600E-
Expressing Cell Lines
Because OV-90 carries the activating BRAFV600E mutation (Estep
et al., 2007), we queried whether BRAFV600E similarly induced
GEF-H1 protein expression. We found that GEF-H1 protein levels
were increased in BRAFV600E-transformedNIH 3T3 cells andwere
sensitive toMEK inhibition (FiguresS2CandS2D).Moreover,GEF-
H1 expression in the human melanoma cell line A375, which
carries an endogenous BRAFV600E mutation, was suppressed
following MEK inhibition (Figure S2E). BRAFV600E expression also
induced a 4.6-fold increase in the normalized Arhgef2 promoter-
mediated reporter expressioncompared toNIH3T3cells express-
ing the Arhgef2 promoter alone, which was suppressed withMEK
inhibition (Figure S2F). Lastly, knockdown of GEF-H1 induced cell
death in BRAFV600E-transformed cells (Figures S2G and S2H).184 Cancer Cell 25, 181–195, February 10, 2014 ª2014 Elsevier Inc.These data indicate that the induction of
GEF-H1 expression and GEF-H1-depen-
dent cell survival extends to other onco-
genes that activate the MAPK pathway.
GEF-H1 Is Necessary for Optimal
MAPK Pathway Activation in
Response to HRASV12
We next sought to investigate the
mechanism underlying the contributionof GEF-H1 to HRASV12-mediated cellular transformation. We
compared the levels of Rho-GTP in control and GEF-H1 knock-
down cells expressing HRASV12 but found no change in Rho-
GTP levels (Figure S3A and S3B), demonstrating that a change
in Rho-GTP cannot account for the contribution of GEF-H1 in
HRASV12-mediated transformation. We therefore investigated
whether elevated levels of GEF-H1 affected the signaling char-
acteristics of upstream components of the RAS/MAPK pathway
as part of a potential positive feedback mechanism. We ex-
pressed HRASV12 in MEFs harboring stable knockdown of
GEF-H1 and probed lysates for phosphorylated forms of
MEK1/2 and ERK1/2 to assess MAPK pathway activity. MEK1/
2 and ERK1/2 were highly phosphorylated in HRASV12-express-
ing MEFs (Figure 4A, lane 2), but, surprisingly, MEK1/2 and
ERK1/2 phosphorylation was significantly reduced in GEF-H1-
depleted cells (Figure 4A, lanes 4 and 6). Expression of an
shRNA-resistant GEF-H1 (rGEF-H1) restored MEK1/2 and
ERK1/2 phosphorylation in response to HRASV12 expression in
GEF-H1 knockdown MEFs (Figure 4A, lane 7). A similar defect
in HRASV12-mediated ERK1/2 phosphorylation was seen in
Figure 3. GEF-H1 Contributes to Cell Survival and Growth in HRASV12-Transformed Cells
(A) GEF-H1 protein levels in NIH 3T3 cells expressing vector, HRASV12, or HRASV12 with a control hairpin (shGFP) or two distinct murine GEF-H1 shRNAs
(shGEFm1 and shGEFm2).
(B)Cellsdescribed in (A)wereprobed for caspase3cleavagebywesternblot 5daysafter infectionwith lentiviral hairpins.Tubulin servedasaprotein loadingcontrol.
(C) Representative images of cell lines described in (A) grown for 10 days in 0.3% agar to form colonies. Scale bars, 200 mm.
(D) Photographs of NCr nude mice 14 days after subcutaneous injection of cells described in (A).
(E) Final mean tumor volumes are shown in (D). Results are the combination of four independent experiments (n = 21 tumors). Error bars indicate ± SEM.
(F) Immunohistochemistry of NIH 3T3-HRASV12 tumor sections stained for cleaved caspase 3. Four tumors were sampled from two independent experiments.
Scale bars, 100 mm.
(G) Bright field images of wild-type or Arhgef2/ MEFs expressing eGFP, eGFP-HRASV12, or eGFP-HRASV12 and Flag-GEF-H1 4 days after transfection and
selection. Scale bars, 100 mm.
See also Figure S2.
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Figure 4. GEF-H1 Is Necessary for Optimal MAPK Pathway Activation in Response to HRASV12
(A) MEFs stably expressing shGFP, shGEFm1, or shGEFm2 were transfected with empty vector or HRASV12 and probed for pERK or pMEK by western blot.
shGEFm2-expressing cells were co-transfected with HRASV12 and Flag-rGEF-H1, Flag-rGEF-H1E243K, or Flag-AKAPLbc. Expression of plasmids was confirmed
by immunoblotting with anti-GEF-H1, anti-RAS, or anti-Flag (AKAPLbc) antibodies.
(B) Real-time NMR measurement of RhoA nucleotide exchange rates in lysates from HEK293T cells expressing eGFP, eGFP-GEF-H1, eGFP-GEF-H1D87–151,
eGFP-GEF-H1E243K, or eGFP-p115RhoGEF. Graphical representation of eGFP-p115RhoGEF-induced nucleotide exchange rate is not to scale as indicated by
breaks in graph, because the rate was 9.4-fold over eGFP-GEF-H1 (r = 0.132 versus r = 0.014). Data are representative of three independent experiments ± SD.
(C) Schematic representation of KSR-1 constructs used in (D).
(D) Pyo-tagged KSR-1 constructs were coexpressed with Flag-GEF-H1 in HEK293T cells. Protein complexes were immunoprecipitated with anti-Flag antibody,
and proteins were detected by immunoblotting with anti-KSR-1 or anti-Flag antibodies.
(E) MEFswere transfected with vector or eGFP-GEF-H1D87–151, andKsr1/MEFswere transfectedwith vector, eGFP-GEF-H1D87–151, eGFP-GEF-H1D87–151 and
Pyo-KSR-1, or Pyo-KSR-1 alone and assayed for pERK by western blot. GEF-H1 and KSR-1 expression was determined by western blot.
See also Figure S3.
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GEF-H1 Is Required for Oncogenic RAS SignalingArhgef2/ MEFs, which was restored by GEF-H1 expression
(Figure S3C, lanes 4 and 5).
To determine the specificity of GEF-H1-dependent MAPK
pathway activation, we attempted to rescue the GEF-H1 knock-
down phenotype by expressing either AKAP-Lbc, the closest
GEF family member to GEF-H1, or p115 RhoGEF, another Rho-
GEF family member. Neither AKAP-Lbc (Figure 4A, lane 9) nor
p115 RhoGEF (Figure S3C, lane 7) rescued MEK1/2 and ERK1/
2 phosphorylation in response to acute HRASV12 expression in
GEF-H1 knockdown or Arhgef2/ MEFs, respectively, despite
9-fold greater catalytic activity of p115RhoGEF compared to
GEF-H1 (Figure 4B). To investigate whether GEF-H1-mediated
MAPK pathway activation was dependent on its GEF activity,
we coexpressed a catalytically inactive, shRNA-resistant form
of GEF-H1 (rGEF-H1E243K, Figure 4B) with HRASV12 in MEFs
depleted of endogenous GEF-H1 and found that MEK1/2 and
ERK1/2 phosphorylation was fully restored (Figure 4A, lane 8).
These findings were confirmed in Arhgef2/ MEFs (Figure S3C,
lane 6). These data show that GEF-H1 potentiates the HRASV12/
MAPK pathway in a manner independent of its GEF activity.
GEF-H1 Is a Component of the KSR-1 Complex and Is
Required for the Dephosphorylation of the Negative
Regulatory Site of KSR-1
Given that GEF-H1 catalytic activity is dispensable for HRASV12-
dependent MAPK pathway activation, we hypothesized that
GEF-H1 may be providing a scaffold function for components
of the MAPK pathway. We investigated whether GEF-H1 could
form a complex with KSR-1, the major scaffold for the MAPK
pathway. We detected an interaction between endogenous
GEF-H1 and endogenous KSR-1 in GEF-H1 immunoprecipitates
fromwild-type, but notArhgef2/, MEFs (Figure S3D). Similarly,
in an overexpression system, we detected an interaction be-
tween KSR-1 and a mutant of GEF-H1 deleted of the negative
regulatory sequences between amino acids 87–151 and un-
bound from microtubules (GEF-H1D87–151, Meiri et al., 2012)
(Figure S3E). To discern which domains of KSR-1 interact with
GEF-H1, we analyzed Flag-GEF-H1 immune complexes from
cells that expressed full-length or a series of Pyo-tagged KSR-
1 deletions (Figure 4C). We found that full-length KSR-1, KSR-1
(1–539), KSR-1(1–424), and KSR-1(542–873) interacted with full-
length GEF-H1 (Figure 4D). These data show that KSR-1 can
form a complex with GEF-H1 and that both the C1 domain and
the kinase domain of KSR-1 contribute to GEF-H1 binding.
We next sought to determine whether ERK1/2 activation by
GEF-H1 was dependent on KSR-1. Expression of the active
GEF-H1D87–151 mutant (Figure 4B) in wild-type MEFs induced
strong ERK1/2 phosphorylation even in the absence of HRASV12
expression (Figure 4E, lane 2), whereas Ksr1/ MEFs were
resistant to GEF-H1D87–151-induced ERK1/2 phosphorylation
(Figure 4E, lane 3 and 4). Re-expression of KSR-1 restored
GEF-H1D87–151-induced ERK1/2 phosphorylation in Ksr1/
cells (Figure 4E, lane 5), whereas re-expression of KSR-1 in the
absence of GEF-H1D87–151 alone had little effect on ERK1/2
phosphorylation (Figure 4E, lane 6). These data confirm that
GEF-H1 requires KSR-1 to positively regulate ERK1/2 activation.
Platelet-derived growth factor (PDGF) or HRASV12 induce the
dephosphorylation of KSR-1 at S392 and its subsequent translo-
cation from the cytoplasm to the plasma membrane (Ory et al.,C2003). We therefore examined the requirement of GEF-H1 for
PDGF-induced KSR-1 membrane translocation (Figure 5A). In
22% (21 of 97) of wild-type cells, KSR-1 translocated from the
cytoplasm to the plasma membrane in a PDGF-dependent
manner (Figure 5A, columns 1 and 2; Figure S4A). By contrast,
only 3.5% of cells (3 of 87) underwent PDGF-dependent mem-
brane translocation in Arhgef2/ cells (Figure 5A, columns 3
and 4; Figure S4A), a defect that was rescued by the expression
of wild-type GEF-H1 (Figure 5A, columns 5 and 6; Figure S4A).
Because translocation of KSR-1 to the plasma membrane
requires dephosphorylation of S392, we queried whether the
S392A point mutant form of KSR-1 could rescue the depen-
dence on GEF-H1 for translocation to the plasma membrane.
We expressed wild-type KSR-1 or KSR-1S392A in Arhgef2/
cells and found that, in the absence of growth factor stimulation,
wild-type KSR-1 was rarely associated with the plasma mem-
brane (9% or 6 of 69 cells, Figures 5B and S4B), whereas
KSR-1S392A efficiently localized to the plasma membrane even
in the absence of GEF-H1 (37% or 28 of 76 cells) (Figure 5B,
columns 1 and 2; Figure S4B). These data show that GEF-H1
is required for the translocation of KSR-1 to the plasma mem-
brane in a manner that depends on the dephosphorylation of
KSR-1 on S392. Re-expression of GEF-H1 and KSR-1 in
Arhgef2/ MEFs was insufficient to induce membrane translo-
cation of KSR-1 in the absence of PDGF treatment (6% or 4 of
67 cells) (Figure 5B, column 3; Figure S4B). However, the
requirement for growth factor-stimulated KSR-1 translocation
to the plasma membrane could be circumvented by the expres-
sion of the non-microtubule-associated form of GEF-H1,
GEF-H1D87–151 (Meiri et al., 2012), with 30% (21 of 71) of cells
exhibiting KSR-1 plasma membrane localization (Figure 5B,
column 4; Figure S4B). These data suggest that the growth factor
dependence of KSR-1 translocation to the plasma membrane is
contingent on the release of GEF-H1 from the microtubule array.
Importantly, we found that the endogenous interaction of
GEF-H1 and KSR-1 was induced between 5–20 min of PDGF
stimulation, correlating with their translocation to the plasma
membrane (Figure 5C). These data suggest that endogenous
complex formation between GEF-H1 and KSR-1 occurs at the
plasma membrane in response to PDGF treatment.
To clarify whether the dependence of HRASV12 on GEF-H1 for
cell survival was mediated through KSR-1, we measured cell
viability following ectopic expression of wild-type KSR-1 or
KSR-1S392A with HRASV12 in Arhgef2/ MEFs and found that
only KSR-1S392A restored cellular viability (Figures 5D and 5E).
These data provide genetic evidence that dephosphorylation of
the negative regulatory site S392 on KSR-1 is the critical target
downstream of GEF-H1 that supports cell survival in HRASV12-
transformed cells.
To determine whether GEF-H1 regulation of the HRASV12/
MAPK cascade is coupled to the dephosphorylation of KSR-1,
we asked whether wild-type KSR-1 or KSR-1S392A could restore
HRASV12-induced ERK1/2 phosphorylation in the absence of
GEF-H1. HRASV12 expression induced ERK1/2 phosphorylation
in control hairpin-expressing MEFs, but not in cells depleted of
GEF-H1 (Figure 5F, lanes 2 and 4). High expression of rGEF-
H1 in GEF-H1-depleted cells greatly enhanced ERK1/2 acti-
vation in response to HRASV12, supporting the model that
increased levels of GEF-H1 result in amplification of the MAPKancer Cell 25, 181–195, February 10, 2014 ª2014 Elsevier Inc. 187
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GEF-H1 Is Required for Oncogenic RAS Signalingcascade (Figure 5F, lane 5). Expression of KSR-1S392A efficiently
restored HRASV12-mediated ERK1/2 phosphorylation in GEF-H1
knockdown cells compared to wild-type KSR-1 (Figure 5F, lanes
6 and 7). These data demonstrate that dephosphorylation of
KSR-1 S392 is sufficient to overcome the GEF-H1-dependence
of HRASV12-mediated ERK1/2 activation.
GEF-H1 Is Required for PP2A-Mediated
Dephosphorylation of KSR-1
In an independent study, we identified GEF-H1 as a PP2A inter-
acting partner in a proteomic screen designed to probe for
proteins that bound to the PP2A catalytic subunit (D.M.,
C.B.M., J.L., M. Mullin, A.-C.G., M.I., and R.R., unpublished
data) and found that GEF-H1 interacts with the B’ regulatory
PP2A subunits (PPP2R5A, PPP2R5B, and PPP2R5E). We
hypothesized that GEF-H1 may function as a bridge between
KSR-1 and PP2A to control KSR-1 S392 dephosphorylation.
First, we confirmed the previously published data showing an
interaction between KSR-1 and the B’ regulatory PP2A subunits
(Figure 6A) (Ory et al., 2003). We observed that GEF-H1 bound to
the same PP2A subunits that interacted with KSR-1 (Figure 6A).
We next determined the regions of GEF-H1 involved in PP2A and
KSR-1 binding by expressing deletion mutants of GEF-H1
(Figure 6B) and probing for the catalytic subunit of PP2A and
KSR-1 in GEF-H1 immune complexes (Figure 6C). Analysis of
GEF-H1 immunoprecipitates revealed that endogenous KSR-1
interacted with full-length GEF-H1, GEF-H1(236–572), and
GEF-H1(236–433). These results localize the binding site for
KSR-1 to the DH domain of GEF-H1, while endogenous PP2Ac
binds to the GEF-H1 PH domain (Figure 6C). These data show
that KSR-1 and PP2A bind to distinct sites on GEF-H1 and sug-
gest that GEF-H1 may function to bridge PP2A to KSR-1.
To determine whether GEF-H1 acts as a bridge to link KSR-1
to PP2A, we stably infected human embryonic kidney 293T
(HEK293T) cells expressing the PP2A B’ subunit with an shRNA
targeting GEF-H1 and probed PP2A immunoprecipitates for
endogenous KSR-1 (Figure 6D). KSR-1 was detected in immune
complexes of PP2A B’ subunits in shGFP-expressing cells, but
not those depleted of GEF-H1. Thus, the interaction between
KSR-1 and PP2A is dependent on GEF-H1. These data support
a model whereby GEF-H1 provides a bridging function to recruit
the PP2A B’ subunits required for the dephosphorylation of the
negative regulatory S392 site on KSR-1 and activation of the
MAPK pathway.Figure 5. KSR-1 Signals through GEF-H1 in Response to PDGF and On
(A) Wild-type or Arhgef2/ MEFs were transfected with eGFP or eGFP-GEF-H1
endogenous KSR-1. Arrows indicate KSR-1 plasmamembrane localization and e
independent experiments.
(B) Arhgef2/ MEFs were co-transfected with KSR-1 or KSR-1S392A and eGFP,
Arrows and scale bars are as in (A), and images are representative of four indep
(C) HEK293T cells were starved for 12 hr and treated with BSA or 25 ng/ml PDGF f
probed for the presence of endogenous KSR-1. Lysates were probed for total l
pathway activation and total protein levels, respectively.
(D) Representative bright field images of wild-type orArhgef2/MEFs expressing
1S392A 72 hr after transfection. Scale bars, 100 mm.
(E) Quantification of the number of viable cells described in (D) 24, 48, and 72 hr
(F) MEFs stably expressing shGFP or shGEFm2 were transfected with vector, HR
Pyo-KSR-1. KSR-1 S392 phosphorylation was assessed with a pS392-specific K
See also Figure S4.
CGiven that dephosphorylation of KSR-1 on S392 is induced in
response to PDGF and oncogenic RAS, we sought to determine
whether the interaction between GEF-H1 and KSR-1 was simi-
larly regulated. We isolated Flag-PPP2R5E immune complexes
from HEK293T cells and probed them for the presence of
GEF-H1 and KSR-1 after PDGF treatment (Figure 6E). Although
GEF-H1 and KSR-1 were not detectable in PPP2R5E immune
complexes in starved cells, both GEF-H1 and KSR-1 were re-
cruited to PPP2R5E immune complexes after 5 min of PDGF
stimulation and disappeared after 15 min (Figure 6E). Moreover,
induction of oncogenic HRAS with 4-OHT induced a protein
complex composed of endogenous KSR-1, GEF-H1, and
PPP2R5E proteins after 20min and extending to 90min following
RAS activation (Figure S5). These data show that PDGF or
HRASV12 induce the formation of a KSR-1, GEF-H1, and
PP2A protein complex. Moreover, the complex appears to be
temporally regulated, suggesting the presence of feedback
mechanisms that attenuate its assembly even with constitutive
activation of the pathway.
GEF-H1 Is Important for the Growth of RAS Mutant
Pancreatic Tumor Xenografts
Over 90% of human pancreatic ductal adenocarcinomas
(PDACs) harbor activating mutations in KRAS (Smit et al.,
1988). We evaluated whether GEF-H1 expression was increased
in PDAC by immunohistochemistry on pancreatic tissue micro-
arrays (TMAs). We probed tissue sections of 14 normal pancre-
atic ducts, 32 PanIN-1 (A and B) lesions, 9 PanIN-2 and IN-3
lesions, and 14 PDAC tumor samples for GEF-H1 expression us-
ing a monoclonal antibody against GEF-H1 (Figure 7A). Normal
pancreatic ducts and PanIN-1 lesions did not express GEF-H1,
whereas greater than 90% (21 out of 23) of the more advanced
histologic grades expressed GEF-H1 (Figures 7A and S6A).
These data demonstrate that GEF-H1 expression is positively
correlated with neoplastic progression of pancreatic tumors.
Treatment of the PDAC cell line PANC-1, harboring a KRASD12
mutation, with MEK inhibitors PD98059 or UO126 resulted in
reduced GEF-H1 levels (Figure S6B). Together, these data
show that GEF-H1 expression is increased in PDAC cells in a
manner that is dependent on MAPK pathway activation.
To determine whether GEF-H1 was necessary for MAPK
pathway activation in PDAC cells, we knocked down GEF-H1
in PANC-1 cells and observed increased KSR-1 S392
phosphorylation and a corresponding decrease in ERK1/2cogenic RAS
and treated with BSA or 25 ng/ml PDGF for 10 min and fixed and stained for
GFP-GEF-H1 localization. Scale bars, 20 mm. Images are representative of four
eGFP-GEF-H1, or eGFP-GEF-H1D87–151 and stained for endogenous KSR-1.
endent experiments.
or 5, 10, or 20min. Endogenous GEF-H1 immune complexes were isolated and
evels of GEF-H1 and KSR-1. pERK and ERK reflect the temporality of MAPK
eGFP-HRASV12, eGFP-HRASV12 + Pyo-KSR-1, or eGFP-HRASV12 + Pyo-KSR-
after transfection; 4 3 104 cells were plated at time 0.
ASV12, or co-transfected with HRASV12 and Flag-rGEF-H1, Pyo-KSR-1S392A, or
SR-1 antibody.
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Figure 6. GEF-H1 Is Required for PP2A-Mediated Dephosphorylation of KSR-1 on S392
(A) Flag-PP2A immune complexes were isolated from stable Flag-PP2A catalytic and regulatory subunit-expressing HEK293T cells using anti-Flag antibodies.
Flag-PP2A complexes were probed for endogenous GEF-H1 and endogenous KSR-1 (rows 2 and 3). Total expression levels of GEF-H1 and KSR-1 in lysates are
shown in rows 4 and 5.
(B) Schematic representation of GEF-H1 constructs used in (C).
(C) Flag-tagged truncated variants of GEF-H1 were expressed in HEK293T cells, and protein complexes were immunoprecipitated with anti-Flag antibodies.
Lysates were probed with anti-KSR-1 or anti-PP2Ac antibodies.
(D) HEK293T cells stably expressing Flag-tagged PP2A regulatory subunits were infected with shGFP or shGEFh2 lentiviruses. Flag-PP2A subunits were im-
munopurified with anti-Flag (row 1) and probed for endogenous KSR-1 (row 2). Flag-PP2A subunit expression (row 3) and GEF-H1 knockdown (row 4) were
confirmed by immunoblotting lysates with Flag and GEF-H1 antibodies, respectively.
(E) HEK293T cells stably expressing Flag-PPP2R5Ewere treatedwith 25 ng/ml PDGF for 0, 5, 10, or 15min. Flag-PPP2R5E immune complexeswere isolatedwith
anti-Flag antibodies and probed for the presence of endogenous GEF-H1 and KSR-1 (left panel). Lysates were probed for total levels of Flag-PPP2R5E,
endogenous GEF-H1 and KSR-1 (right panel).
See also Figure S5.
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(Figure 7B). Expression of shRNA-resistant GEF-H1D87–151
restored the basal levels of phosphorylated KSR-1 and ERK1/2
in GEF-H1-depleted cells (Figure 7B). These data indicate
that GEF-H1 is both necessary and sufficient for KSR-1
S392 dephosphorylation and ERK1/2 activation in PDAC
cells harboring endogenous RAS mutations. Expression of
KSR-1S392A, but not wild-type KSR-1, corrected the defect in
the phosphorylated ERK levels in GEF-H1 knockdown cells,
showing that active KSR-1 can circumvent the need for GEF-
H1 in PANC-1 cells (Figure 7B).
We tested the contribution of GEF-H1 to the in vitro cell
growth of four human KRAS mutant pancreatic cancer derived
cell lines including PANC-1 Panc 08.13, Panc 04.03, and
PL-45 (Figures S6C–S6F). These cell lines displayed varying
sensitivity to GEF-H1 depletion for cell growth (a 50%, 90%,
80%, and 65% reduction, respectively) compared to control
hairpin-expressing cells. Of the six pancreatic lines that we
had tested, we examined the contribution of GEF-H1 to tumor
growth in three of these lines, PANC-1 (KRASD12), HPAF-II
(KRASD12), and BxPC3 (wild-type KRAS), in immune-deficient
mice. PANC-1 and HPAF-II cells exhibited profound attenuation
of tumor growth relative to control hairpin cells (Figures 7C, S6G,
and S6H). The tumor growth of BxPC3 cells was not affected
by depletion of GEF-H1, highlighting the dependency of onco-
genic RAS on GEF-H1 (Figures 7C and S6I). In addition,
increased tumor-associated caspase 3 cleavage was observed
in PANC-1 xenografts (Figure S6J). Collectively, our data
demonstrate an amplifying feedback loop involving GEF-H1 in
the RAS/MAPK pathway across a variety of cell types expressing
different mutant RAS family members. These data support the
model that GEF-H1 is important for the growth of tumor cells
harboring activating mutations in RAS.
DISCUSSION
Signaling through the RAS/MAPK pathway is gated by KSR-1,
a highly conserved scaffold protein that ensures strict spatio-
temporal regulation of ERK activation. Genetic studies have
demonstrated a critical requirement of KSR-1 for growth
factor-mediated signaling through the RAS/MAPK pathway
(Sieburth et al., 1999; Lozano et al., 2003) and the formation of
HRASV12-dependent tumors (Xiao et al., 2010). The requirement
of KSR-1 in HRASV12-mediated transformation is strictly depen-
dent on the dephosphorylation of KSR-1 at S392 by PP2A
(Razidlo et al., 2004). In this study, we provide a mechanistic
explanation of how the B’ subunit is recruited to the PP2A/
KSR-1 complex and uncover a positive feedback loop involving
the RhoGEF GEF-H1 that is necessary for HRASV12-mediated
transformation. We show that Arhgef2 is a direct transcriptional
target of the RAS/MAPK pathway, and its elevated protein
expression is similarly responsive to oncogenic BRAF and H-,
K-, and NRAS family members. We demonstrate that GEF-H1
contributes to the growth and survival of BRAFV600E and
HRASV12-transformed NIH 3T3 cells and PDAC xenografts. We
anticipate that there may be examples of escape mechanisms
whereby some RAS mutant tumors no longer depend on
the GEF-H1 amplifying loop, which will be an area of future
investigation.CThe discovery that a RhoGEF is involved in a positive feedback
loop for the MAPK pathway suggests a model whereby amplifi-
cation of the MAPK pathway could be coupled to signal diversi-
fication through the activation of RhoA, a known component of
the RAS transformation program (Qiu et al., 1995; Prendergast
et al., 1995; Sahai et al., 2001; Chen et al., 2003). Our data
suggest that oncogenic RAS induces RhoA-GTP independently
of GEF-H1, a finding consistent with the previously reported
model that a decrease in p190RhoGAP activity, rather than an
increase in total cellular RhoGEF activity, controls RhoA-GTP
levels in HRASV12-transformed cells (Chen et al., 2003). The
observation that overexpression of GEF-H1 is sufficient to
increase MEK1/2 and ERK1/2 phosphorylation raises the possi-
bility that the oncogenic potential of GEF-H1 ismediated through
its capacity to increase cellular Rho-GTP levels and/or activate
the MAPK pathway.
An important implication that follows from this study is the
possibility that mitogenic signals conveyed through the MAPK
pathway might be coupled to microtubule function through
GEF-H1, thereby coordinating growth signals with changes in
cell shape, migration, and/or morphogenesis. We show that
the mutant GEF-H1D87–151, unable to interact with the micro-
tubule array, is largely cytoplasmic (Meiri et al., 2012) and is
able to induce KSR-1 membrane translocation and ERK1/2
phosphorylation in the absence of either PDGF or oncogenic
RAS. These findings suggest that the release of GEF-H1 from
microtubules links HRASV12 to KSR-1 function. This idea is
supported by the observations that depolymerization of micro-
tubules potently activates components of the MAPK pathway
through currently unknown mechanisms (Birukova et al., 2005;
Guo et al., 2012; Hayne et al., 2000). Active HRAS contributes
to microtubule instability that may promote the invasive behavior
of transformed cells and reinforce the GEF-H1 positive feedback
loop on the MAPK pathway (Harrison and Turley, 2001). In addi-
tion, ERK phosphorylation and activation of GEF-H1 (Fujishiro
et al., 2008) might trigger its release from microtubules, where
it can interact with cytosolic KSR-1. The signaling events that
coordinate the spatial coupling of GEF-H1 with cytosolic
KSR-1 remain to be elucidated.
The identification of GEF-H1 as a component of the RAS
signaling circuitry is part of an emerging role of RhoGEFs in
RAS signaling. TIAM1, a Rac exchange factor, is directly acti-
vated by RAS-GTP through a RAS binding motif in its N terminus
and is required for RAS-induced skin tumors (Lambert et al.,
2002; Malliri et al., 2002). The RhoGEF AKAP-Lbc was shown
to couple PKA to KSR-1 through its A-kinase anchoring protein
scaffold function (Smith et al., 2010). GEF-H1may also be impor-
tant in other genetic contexts, because it has been reported to
contribute to the growth and survival of cell lines harboring
stabilizing p53 mutations and those expressing the oncogene
hPTTG1 (Mizuarai et al., 2006; Liao et al., 2012).
The GEF-H1-mediated feedback loop adds to a growing num-
ber of other feedback loops that control flux through the MAPK
pathway. ERK1/2-dependent phosphorylation of upstream
components SOS, RAF, and EGFR (Buday et al., 1995; Porfiri
and McCormick, 1996; Dougherty et al., 2005; Ritt et al., 2010;
Heisermann et al., 1990; Li et al., 2008) dampens further pathway
activation, and a second, kinetically slower, negative feedback
loop involves the induction of DUSP phosphatases that directlyancer Cell 25, 181–195, February 10, 2014 ª2014 Elsevier Inc. 191
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ration of the MAPK pathway with both positive and negative
feedback loops ensures that the amplitude and persistence of
the MAPK signal is both robust and tunable so as to serve
the multiplicity of developmental and mitogenic functions it
provides.
In summary, we have found that the induction of GEF-H1 in
RAS mutant cells amplifies MAPK signaling and contributes
to pancreatic tumor xenograft growth. The identification of
GEF-H1 as a component of a positive amplifying loop critical
for HRASV12-mediated transformation therefore provides mech-
anistic insight into the manifold features of the transformation
program activated by mutant RAS in human cancers.
EXPERIMENTAL PROCEDURES
Animal Studies
All animal studies were carried out using protocols that have been approved by
the University Health Network Animal Care Committee. Detailed experimental
procedures are provided in Supplemental Experimental Procedures.
Cell Treatments
ER:HRASV12 MEFs were starved in DMEM containing 0% FBS for 16 hr then
treated with 100 nM 4-OHT (Sigma). For MEK and PI3K inhibition experiments,
cell lines were cultured in complete medium and incubated with PD98059,
UO126, or LY294002 (Sigma) diluted in DMSO (Sigma) for 48 hr. For immuno-
fluorescence studies, MEFs were starved for 24 hr in 0% FBS and treated in
DMEM containing 10 mM HEPES and 0.5 mg/ml fatty acid-free BSA (A8806,
Sigma). PDGF (Sigma) was suspended in HBSS containing 0.5 mg/ml fatty
acid-free BSA and 20 mM HEPES to a stock concentration of 1 mM.
Luciferase Reporter Assays
The regulatory sequence of murineArhgef2 (nucleotides 62–1,968 upstream of
the transcription start site) was PCR-amplified from mouse BAC clones and
inserted into the pGL3 luciferase vector to generate pArhgef2Luc (Promega,
E1910). MEFs or NIH 3T3 cells expressing empty vector, KRASD12, or
BRAFV600E were plated in a 24-well plate in triplicate at 73 104 cells/well. After
16 hr, cells were cotransfected with 50 ng pArhgef2Luc, empty vector, T7-
HRASV12, or T7-KRASD12 expression plasmids and 1 ng phRL-SV40 (Prom-
ega) using LipoD293 (SignaGen, SL100668) or Lipofectamine 2000 (Invitrogen)
according to themanufacturer’s instructions. Twenty four hours after transfec-
tion, cells were lysed and assayed for firefly and renilla luciferase activity using
the Dual-Luciferase Reporter System (Promega). Where indicated, cells were
treated with DMSO, PD98059, UO126, or LY294002 for 16 hr prior to cell lysis.
Immunohistochemistry
In this study, we used a human pancreatic TMA generated in a previously pub-
lished study (Al-Aynati et al., 2004). The use of this TMA in this study was
approved by the University Health Network Research Ethics Board (protocol
04-0018T). Immunohistochemistry was performed using the Biotin-Streptavi-
din-HRP detection system and a human GEF-H1 antibody (14B11 mouse
monoclonal antibody) at 1:500 dilution. To evaluate the expression levels of
GEF-H1, staining intensity in the ductal cells or lesions were judged by two
pathologists and scored as 2 (strong staining), 1 (weak staining), or 0 (absentFigure 7. GEF-H1 Is Important for the Growth of RAS Mutant Pancreat
(A) GEF-H1 expression in tissue sections of normal pancreatic ducts, PanIN-1B
histochemistry. GEF-H1 staining is represented in brown. Scale bars, 60 mm (No
(B) PANC-1 cells were infected with shGFP or shGEFh2 and transfected with Flag
indicated proteins by immunoblotting.
(C) Indicated cells were infected with shGFP, shGEFh1, or shGEFh2, and GEF-H
control (insets). Growth curves of xenografts derived from 23 105 cells are depicte
representative images of dissected tumors from one of two experiments perform
independent experiments ± SD of n = 5 tumors per condition. N.S. denotes that
See also Figure S6.
Cstaining). For NIH 3T3 xenograft studies, tumor sections were fixed in OCT
medium, flash frozen in methylbutanol, and stored at 80C before being
sent for immunohistological processing at Toronto General Hospital’s Pathol-
ogy Department. PDAC xenograft tumors were fixed in 10% formalin, paraffin
embedded, and sent for immunohistological processing at the Applied Mole-
cular Profiling Lab (Princess Margaret Hospital, Toronto, Canada). Tumor
sections were probed for caspase 3 cleavage using anti-cleaved caspase 3
(Asp 175) antibody (CST 9661).
Promoter Analysis of GEF-H1
Phylogenetic footprinting analysis was performed using mouse and human
sequences of ARHGEF2 (NM_1162383.1 and NM_004723.3, respectively)
(Zhang and Gerstein, 2003). Sequences were aligned to the genome with
BLAT, where the TSS was ascertained, and DNA 1 kb downstream (30) and
5 kb upstream (50) were pulled from the database. The 5 kb and 1 kb segments
were analyzed separately using Consite (Sandelin et al., 2004), employing all
matrices found in the public Jaspar database.
Statistical Analyses
Values are expressed as means ± SD. Paired Student’s t tests (Kirkman, 2006)
were performed to determine statistical significance between samples.
Experiments were performed at least three times, and means with p < 0.05
were considered statistically significant.
See Supplemental Experimental Procedures for descriptions of all other
experimental procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2014.01.025.
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